SCHEMBL16631238

SCHEMBL16631238

C#Cc1[nH]c(=O)c(C)nc1[C@@H]1O[C@H](CO)C(O)[C@@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UMPS P11172 1/20 0.39
PYGL P06737 3/20 0.36
KDM4E B2RXH2 1/20 0.36
GMNN O75496 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
STAT6 P42226 1/20 0.36
HIF1A Q16665 1/20 0.36
PNP P00491 3/20 0.35
SLC5A2 P31639 2/20 0.35
GSK3B P49841 1/20 0.34
OGA O60502 2/20 0.34
HEXA P06865 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631169 0.90 CDA (0.32) UMPSKDM4EGMNNLMNAMAPT
SCHEMBL16631507 0.88 OGA (0.32) LMNATSHRPNPSLC5A2GSK3B
SCHEMBL16631252 0.87 UMPS (0.39) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL16631820 0.86 UMPS (0.43) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL7214397 0.81 UMPS (0.44) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL16631308 0.81 UMPS (0.41) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL16631625 0.81 UMPS (0.41) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL18079913 0.77 CDA (0.32) UMPSPNPGSK3BOGAHEXB
SCHEMBL16631239 0.77 PYGL (0.42) UMPSPYGLKDM4EGMNNLMNA
SCHEMBL16631264 0.76 SLC5A2 (0.41) SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 UMPS 114/4885PYGL 649/4885KDM4E 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.